Please enable JS

DISCOVER

CT-SCOUT™

Success is when the time to access an innovative treatment is reduced.

CT-SCOUT™ is a multi-device application aiming at facilitating the recruitment of patients in clinical studies...

It assists the investigational team in detecting the studies for which a patient is potentially eligible according to his/her current health conditions.

Access to CT-SCOUT™

The digital solution to boost patient recruitment in clinical trials

Transforms all physician into real time recruiters
Anywhere, anytime
On any device
Easy to use

CT-SCOUT™ unique features

1. An efficient algorithmic model

2. Real-time detection

3. Simplified
process

Therapeutic Expertise

Gastroenterology

Crohn disease
Ulcerative colitis

Dermatology

Psoriasis
Atopic dermatitis
Hidradenitis suppurativa

Rheumatology

Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis

200 +

studies registered (industrial & academic)

1000 +

users registered

170 +

centers in various countries (Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, UK…)

7000 +

Patients detected

Figure: Total R&D/clinical trials pipeline size, by year 2000-2022

They are so many drugs in development that it is extremely challenging to finds the way to one of them, as a patient or as a site, or to secure a high visibility on one of them for a Sponsor. CT-SCOUT™and ToTem4me facilitate the match between the patients and the studies.

50%

OF STUDIES FAIL TO MEET PATIENT RECRUITMENT DEADLINES

However, millions of patients visit clinical sites every day.
CT-SCOUT help investigators identify the ones that could benefit from a clinical study.

80%

OF THE PATIENTS WOULD WELCOME THE OPPORTUNITY TO PARTICIPATE TO A CLINICAL STUDY

Patients have become actors of their treatment conditions.
ToTem4me help them identify potential opportunities through clinical studies.

0.02%

OF THE PATIENTS ARE BEING OFFERED TO PARTICIPATE TO A CLINICAL STUDY

But 80% of patients would accept to participate t a clinical study.
CT-SCOUT contributes to increase the percentage of patients considered for clinical research.

2

WEEKS SET-UP TIME

No more than 2 weeks are required to get CT-SCOUT
or ToTem4me deployed for a clinical study

As a summary

Assist investigational teams in their clinical research activities.

Shorten clinical trials by boosting detection of patients potentially eligible to clinical trials.

Allow patients’ earlier access to innovative and life-saving treatment.

LATEST NEWSOUR NEWS >

telemedecine technologies news

Quality Isn’t Just a Checkbox — Can Better Workforce Skills Drive Lower Costs?

November 27, 2025

Med City News Healthcare quality isn’t improving at scale, despite advances in technology, because many systems treat it as another compliance task rather than a priority. Stephanie Mercado, CEO of the National Association for Healthcare Quality (NAHQ), argued that investing in workforce skills and standardizing roles can drive safer, higher-quality care while delivering measurable cost […]

READ MORE
telemedecine technologies news

Truth in Reporting Clinical Trial Efficacy: A Call for Action

November 27, 2025

Trial Site News Clinical trial reporting of treatment efficacy is the foundation of public trust in medicine. Yet pharmaceutical companies often report efficacy measured as a relative risk reduction (RRR) while omitting the more relevant absolute risk reduction (ARR). This statistical sleight of hand can make clinically insignificant benefits look spectacular! Consider a simple example A risk is […]

READ MORE
telemedecine technologies news

Simplifying Patient Access And Building Trust Using AI

November 27, 2025

Med City News AI and advanced analytics can help organizations move beyond incremental fixes, streamlining access and improving patient experience, without overburdening staff or budgets. Payers and providers are eager to elevate the patient journey, but for many patients, it still begins with friction. Extended wait times, complex intake processes, and unclear billing can derail […]

READ MORE